Bayer AG: Review of Rivaroxaban Data Presented at the 49th Annual Meeting of the American Society of Hematology (ASH) - Investor Conference Call on December 11, 2007
LEVERKUSEN, Germany, Dec. 3, 2007--Findings from three phase III clinical trials will be presented at the American Society of Hematology (ASH) Annual Meeting. The studies evaluated rivaroxaban in head-to-head comparison with enoxaparin, the current standard of care, for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery. The presentations will highlight results from the recently-completed RECORD1 and RECORD2 studies in total hip replacement surgery as well as additional data from the RECORD3 trial, which evaluated rivaroxaban in total knee replacement surgery.
On this occasion a conference call for investors and analysts will be held on December 11, 2007. Starting at around 2:00 p.m. CET (1:00 p.m. GMT) live on the Internet, Bayer AG will be broadcasting the speech and discussion of the Investor Conference Call. With Dr. Kemal Malik, Head of Global Development at Bayer Schering Pharma, Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development, and Dr. Alexander Rosar, Head of Investor Relations.
A recording of the conference call will be available as from 7:00 p.m. CET (6:00 p.m. GMT).
The audio transmission and recording can be accessed on these sites:
English: http://www.investor.bayer.com German: http://www.investor.bayer.de
Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com
If you have any questions, please contact:
Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Ilia Kürten (+49-214-30-35426) Ute Menke (+49-214-30-33021) Judith Nestmann (+49-214-30-66836) Dr. Olaf Weber (+49-214-30-33567)
